Source:http://linkedlifedata.com/resource/pubmed/id/15941958
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2005-6-8
|
| pubmed:abstractText |
To test the hypothesis that 5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms modify the risk of pancreatic cancer, we conducted a hospital-based, case-control study involving 347 patients with newly diagnosed pancreatic adenocarcinoma and 348 healthy controls, frequency matched by age, sex, and race. MTHFR polymorphisms were determined using the PCR-RFLP method. Association of these polymorphisms with the risk of pancreatic cancer was estimated by unconditional logistic regression analysis. We found that the C667T (but not the A1298C) polymorphism had a significant main effect on the risk of pancreatic cancer. The frequencies of the MTHFR 667CC, 667CT, and 667TT genotypes were 49.5%, 38.6%, and 11.9%, respectively, among cases compared with 48.5%, 45.0%, and 6.5%, respectively, among controls. Individuals with the 667TT genotype displayed a 2-fold increased risk for pancreatic cancer compared with those with the CC/CT genotypes [adjusted odds ratio (OR), 2.14; 95% confidence interval (95% CI), 1.14-4.01]. Multivariate analyses found that the effect of the 677TT genotype on the risk of pancreatic cancer was present among ever smokers (OR, 5.53; 95% CI, 2.0-15.3) and ever alcohol drinkers (OR, 3.16; 95% CI, 1.30-7.69) but not in never smokers (OR, 0.82; 95% CI, 0.33-2.06) and never drinkers (OR, 1.42; 95% CI, 0.56-3.62). Furthermore, a positive interaction between the MTHFR TT genotype and heavy smoking or heavy alcohol consumption was detected. The OR (95% CI) of pancreatic cancer was 6.83 (1.91-24.38) for heavy smokers among the TT carriers compared with never smokers with the CC/CT genotypes and 4.23 (0.88-20.3) for heavy drinkers with the TT genotype compared with nondrinkers with the CC/CT genotypes. These observations support a role for folate metabolism in pancreatic cancer, especially among smokers and heavy drinkers.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1055-9965
|
| pubmed:author |
pubmed-author:AbbruzzeseJames LJL,
pubmed-author:AhmedMahaM,
pubmed-author:BondyMelissa LML,
pubmed-author:ChouTa-HsuTH,
pubmed-author:EvansDouglas BDB,
pubmed-author:HassanManal MMM,
pubmed-author:JiaoLiL,
pubmed-author:LenziRenatoR,
pubmed-author:LiDonghuiD,
pubmed-author:PistersPeter WPW,
pubmed-author:WolffRobert ARA,
pubmed-author:YagúeDD
|
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1470-6
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:15941958-Adenocarcinoma,
pubmed-meshheading:15941958-Adult,
pubmed-meshheading:15941958-Aged,
pubmed-meshheading:15941958-Alcohol Drinking,
pubmed-meshheading:15941958-Case-Control Studies,
pubmed-meshheading:15941958-Female,
pubmed-meshheading:15941958-Folic Acid,
pubmed-meshheading:15941958-Genotype,
pubmed-meshheading:15941958-Humans,
pubmed-meshheading:15941958-Male,
pubmed-meshheading:15941958-Methylenetetrahydrofolate Reductase (NADPH2),
pubmed-meshheading:15941958-Middle Aged,
pubmed-meshheading:15941958-Odds Ratio,
pubmed-meshheading:15941958-Pancreatic Neoplasms,
pubmed-meshheading:15941958-Polymorphism, Genetic,
pubmed-meshheading:15941958-Risk Factors,
pubmed-meshheading:15941958-Smoking
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer.
|
| pubmed:affiliation |
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. dli@mdanderson.org
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|